Shineco, BICC Partner for Blockchain Cell Asset Redemption

Shineco Inc. has entered into a strategic cooperation agreement with BICC Pte Ltd to promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. This collaboration marks a new phase for the RWA ecosystem, advancing from technical integration to real-world application. The partnership builds on Shineco's prior initiatives and lays a solid foundation for the digital application of cell assets.

Shineco Inc. (NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, has entered into a strategic cooperation agreement with Singapore-based BICC Pte Ltd to promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. This collaboration marks a new phase for the RWA ecosystem, advancing from technical integration to real-world application.

The partnership builds on Shineco's prior initiatives, including establishing a Cell Digital Division, signing an agreement with Plus Me Limited for on-chain cell asset management and marketing ecosystems, and acquiring a 51% stake in Xi'an Dong'ao Health Management Co., Ltd. These efforts lay a solid foundation for the digital application of cell assets.

Under the cooperation framework, Plus Me will provide full-lifecycle digital management for Shineco's compliant mesenchymal stem cells on the Ethereum mainnet, generating "digital identities" and issuing ERC-1400/ERC-20 standard "Cell Reimbursement Vouchers." Following the collaboration with BICC, BICC's iPSC stem cell storage services will be integrated into Shineco's blockchain system. Users holding "Cell Reimbursement Vouchers" will be able to redeem them in designated BICC scenarios, forming a cross-enterprise service ecosystem.

The offline support front will be addressed by Shineco's established "storage + reinfusion" network through the acquisition of Xi'an Dong'ao Health. BICC's distribution network of 3,000+ sales representatives will serve as extended nodes of this network, allowing users to complete voucher verification and cell therapy services at BICC's Asian service centers. This addresses the inefficiencies of traditional cross-regional cell service circulation.

Additionally, BICC's clinically validated wound-healing solutions, serum-free media patents, cell banking services, iPSC-derived therapies, and exosome delivery technology will synergize with Shineco's extracellular vesicle-derived products business. Technical parameters will be incorporated into the blockchain asset valuation system to enhance the technical endorsement of on-chain assets.

In terms of division of responsibilities, Shineco will focus on cell quality and offline network standardization, while BICC will emphasize user services and scenario integration. Both parties will collaborate with technical partners to adapt on-chain modules and compliance tools, ensuring all initiatives strictly adhere to local regulations and internal risk controls.

Jennifer Zhan, CEO of Shineco, stated, "The collaboration with BICC will tightly integrate 'standards and scenarios,' exploring verifiable application paths within a compliance framework. Shineco is transitioning from a single technical service provider to a global cell economy infrastructure provider. We welcome more biological cell companies to join the ecosystem and will continue to update on project progress."

BICC Pte Ltd, founded in 2024, is an innovative biotechnology holding company that unites a world-class team of scientists and medical experts specializing in stem cell treatments and artificial intelligence. With a strategic presence across Asia, BICC leverages its proprietary stem cell technologies, such as patented serum-free media, iPSC-derived therapies, and clinically proven wound-healing applications, alongside personalized cell banking services.

The collaboration between Shineco and BICC represents a significant advancement in the field of regenerative medicine and blockchain technology. The successful implementation of this initiative will depend on regulatory acceptance of tokenized biological assets, technical robustness of the blockchain implementation, and the ability to navigate complex technical, regulatory, and practical hurdles across multiple jurisdictions.

References:
[1] https://finance.yahoo.com/news/shineco-nasdaq-sisi-bicc-tech-103000251.html
[2] https://www.stocktitan.net/news/SISI/shineco-nasdaq-sisi-bicc-from-tech-on-chain-to-global-redeemability-g4ks0zkl4ebt.html